Top Markets
Coin of the day
Kyverna Therapeutics, Inc. Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

KYTX
Clasificación en acciones #13175
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Precio por acción
$8.46
Última sincronización: 2026-08-28
Capitalización bursátil
$514.33M
Cambio (1 día)
-2.08%
Cambio (1 año)
128.03%
País
US
Comercio Kyverna Therapeutics, Inc. (KYTX)

Categoría

Historial de desdoblamientos de acciones de Kyverna Therapeutics, Inc. (KYTX)
La acción Kyverna Therapeutics, Inc. (símbolo: KYTX) tuvo un total de 0 desdoblamientos.
El desdoblamiento más reciente ocurrió el Aug 31, 2026.
Una acción KYTX comprada antes de Aug 31, 2026 equivaldría hoy a 0 acciones KYTX.
Lista de desdoblamientos de acciones
Año Desdoblamiento Multiplicador Multiplicador acumulado
Not enough data for the provided dates.
Desdoblamientos de acciones de empresas similares o competidoras
Empresa Número de desdoblamientos de acciones Multiplicador acumulado País
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH